Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study
{{output}}
Background: GLP-1 receptor agonists and SGLT2 inhibitors improve cardiometabolic risk factors in type 1 diabetes, but lack approval, partly due to safety concerns. We aimed to assess the use of these drugs in a national populatio... ...
